As Florida’s legislative session gets underway, lawmakers there are considering tying prescription drug prices in the state to those in other countries that rely on quality-adjusted life years (QALYs) to value health services and treatments.
|
The Partnership to Improve Patient Care (PIPC) recently submitted a letter to the Minnesota Prescription Drug Affordability Board (PDAB) to share concerns of patients and people with disabilities related to the PDAB’s potential use of cost effectiveness analyses.
Since passage of the Inflation Reduction Act, PIPC has worked collaboratively with organizations representing patients and people with disabilities to amplify the perspectives of those with lived experience in the implementation of the Medicare Drug Price Negotiation Program.
The Partnership to Improve Patient Care (PIPC) and 34 organizations representing patients, people with disabilities, and older adults submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the third cycle of the Medicare Drug Price Negotiation Program.
PIPC Chairman Tony Coelho recently penned a letter to Nevada Governor Joe Lombardo urging a veto of legislation (AB 259) that would discriminate against patients, people with disabilities. and older adults.
PIPC Chairman Tony Coelho recently penned a letter to the Maryland Prescription Drug Affordability Board (PDAB) expressing concerns about the PDAB's methodology for setting the Upper Payment Limit (UPL) for selected drugs.
PIPC submitted a comment letter to the Washington Prescription Drug Affordability Board (PDAB) highlighting the concerns of patients and people with disabilities related to the PDAB’s potential use of discriminatory cost effectiveness analyses.
PIPC recently sent a letter to Senator Bill Ferguson and Delegate Adrianne Jones urging Maryland's Legislative Policy Committee to reject the Prescription Drug Affordability Board's (PDAB) proposed Upper Payment Limit (UPL) plan.
PIPC recently submitted comments to the Oregon Prescription Drug Affordability Board (PDAB) to avoid using studies that rely on discriminatory metrics such as the Quality-Adjusted Life Year (QALY) that have detrimental implications for access to needed care and treatment. The letter also encourages the Oregon PDAB to include patients and people with disabilities throughout its decision-making process.
38 organizations representing patients and people with disabilities strongly urged the Maryland Prescription Drug Affordability Board (PDAB) to prioritize the perspectives of people whose care may be impacted by your decisions as it works to finalize a Plan of Action for Implementing the Process for Setting Upper Payment Limits
|
Topics
All
Archives
October 2025
|
